The life sciences industry runs on data. Clinical trial results, regulatory submissions, manufacturing quality records, patient outcomes, supply chain traceability — these aren't just operational assets. They are the scientific and commercial backbone of every product on the market. This makes mergers, acquisitions and divestitures uniquely complicated. When a large pharmaceutical company acquires a biotech, it’s buying more than intellectual property and headcount. It's inheriting years of research, clinical data, validated systems, regulatory history and the compliance obligations that come with all of it. When a company spins off a business unit, it has to surgically separate data that has been commingled for decades, often under strict regulatory and legal timelines.
The traditional approach to this problem can be time-consuming and exceedingly expensive. Snowflake allows organizations to minimize these timelines, while also protecting the most valuable data assets.
The life sciences M&A data problem
Most companies underestimate the data complexity of a deal until they're already in it. Some of the challenges they encounter are specific to the life sciences industry:
Regulatory continuity: Drug development data — such as clinical trial records, adverse event reports and Corrective and Preventive Action (CAPA) documentation — must remain intact and accessible during any transition. An FDA inspection doesn't pause because two companies are integrating. Good practice (GxP)-validated systems cannot simply be migrated without documentation, validation protocols and change control.
